Marcin Kubeczko, Medical Oncologist and Radiation Oncologist at Maria Sklodowska-Curie National Research Institute of Oncology, shared on LinkedIn:
“Some conferences bring together the breast cancer community, where we regularly reconnect with familiar faces and colleagues from around the world.
Others bring together researchers and clinicians from different fields of oncology, offering a different perspective and the opportunity to meet people we might not otherwise cross paths with.
The 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care in Tampa, Florida, was one of those meetings! A great opportunity for interesting discussions, new connections, and sharing our research on FDG PET/CT in breast cancer.”
About the Symposium
The 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care is an international scientific meeting held in Tampa, Florida, bringing together researchers, oncologists and healthcare professionals from different fields of oncology. The symposium provides a platform to share research, discuss advances in cancer diagnosis and treatment, and encourage international collaboration. Its focus includes innovative therapies, precision medicine, biomarkers, clinical research and improving patient care.
About Marcin Kubeczko
Marcin Kubeczko is a Polish medical oncologist and radiation oncologist based at the Maria Skłodowska-Curie National Research Institute of Oncology in Gliwice, Poland. His clinical and research work focuses primarily on breast cancer, particularly advanced breast cancer and the integration of systemic treatments with radiotherapy.
Research and achievements
- Received first prize from the Polish Society of Clinical Oncology in 2025 for the best English-language publication of the previous year, recognising his research on radiotherapy for bone metastases in breast cancer patients treated with CDK4/6 inhibitors.
- Has published research investigating the combination of targeted breast cancer treatments and radiotherapy.
- Has explored the potential of FDG PET/CT as a predictor of treatment response in advanced breast cancer.
You may also be interested in: